Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6J5KY)

Drug Name

PMID8410973C3 Drug Info

Synonyms

GTPL8634; BDBM50008139; 137302-35-3

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Cathepsin E (CTSE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID8410973C2	DMEITGU	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------

Drug(s) Targeting Cathepsin D (CTSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID10498202C1	DMXE0F2	Multiple sclerosis	8A40	Clinical trial	[2]
CI-992	DMBHYIJ	Hypertension	BA00-BA04	Terminated	[3]
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[4]
Grassystatin a	DM1PWX2	Discovery agent	N.A.	Investigative	[5]
KNI-10006	DMMISH6	Discovery agent	N.A.	Investigative	[6]
GRL-7234	DMR93MK	Discovery agent	N.A.	Investigative	[7]
S-Methylcysteine	DMAMRKS	Discovery agent	N.A.	Investigative	[4]
Carbocyclic Peptidomimetic	DM87SOX	Discovery agent	N.A.	Investigative	[8]
N-Aminoethylmorpholine	DMWXBYC	Discovery agent	N.A.	Investigative	[4]
1h-Benoximidazole-2-Carboxylic Acid	DMNZAVE	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cathepsin D (CTSD)	TTPT2QI	CATD_HUMAN	Inhibitor	[1]
Cathepsin E (CTSE)	TTLXC4Q	CATE_HUMAN	Inhibitor	[1]
Pepsinogen-5 (PGA5)	TTKZ864	PEPA5_HUMAN	Inhibitor	[1]
Progastricsin pepsinogen C (PGC)	TT7K6AD	PEPC_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. J Med Chem. 1993 Sep 3;36(18):2614-20.
2	Synthesis and structure activity relationships of novel small molecule cathepsin D inhibitors. Bioorg Med Chem Lett. 1999 Sep 6;9(17):2531-6.
3	Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors. J Med Chem. 1992 Jul 10;35(14):2562-72.
4	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
5	Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. J Med Chem. 2009 Sep 24;52(18):5732-47.
6	alpha-Substituted norstatines as the transition-state mimic in inhibitors of multiple digestive vacuole malaria aspartic proteases. Bioorg Med Chem. 2009 Aug 15;17(16):5933-49.
7	Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem. 2007 May 17;50(10):2399-407.
8	Structure-based design, synthesis, and memapsin 2 (BACE) inhibitory activity of carbocyclic and heterocyclic peptidomimetics. J Med Chem. 2005 Aug 11;48(16):5175-90.